The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate.

The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Described herein are Δ.sup.9-THC prodrugs, methods of making Δ.sup.9-THC prodrugs, formulations comprising Δ.sup.9-THC prodrugs and methods of using Δ.sup.9-THC. One embodiment described herein relates to the transdermal administration of a Δ.sup.9-THC prodrug for treating and preventing diseases and/or disorders.

The present invention is directed to a personal care composition comprising azoxystrobin having a minimum inhibitory concentration (MIC) of less than 1.0 ppm against Malassezia and at least a 4 times or greater MIC against Malassezia compared to strobilurins selected from the group consisting of pyraclostrobin, fluoxastrobin, dimoxystrobin, kresoxim-methyl, trifloxystrobin, or orysastrobin.

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.

Described herein are retinoic acid related-related orphan nuclear receptor (ROR) modulators and methods of utilizing RORγ modulators in the treatment of dermal diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Described herein are retinoic acid related-related orphan nuclear receptor (ROR) modulators and methods of utilizing RORγ modulators in the treatment of dermal diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.